Takeda Pharmaceutical (TAK) Current Taxes (2018 - 2026)

Takeda Pharmaceutical's Current Taxes history runs 9 years deep, the most recent figure standing at $624.1 million for Q1 2026.

• On a quarterly basis, Current Taxes fell 28.67% year-over-year to $624.1 million in Q1 2026; TTM through Mar 2026 was $624.1 million, a 28.67% decrease from a year earlier, with the FY2026 full-year figure at $650.2 million, down 25.81% from the prior year.
• Current Taxes eased to $624.1 million in Q1 2026 per TAK's latest filing, from $963.9 million in the prior quarter.
• Across five years, Current Taxes topped out at $1.9 billion in Q2 2022 and bottomed at $624.1 million in Q1 2026.
• The 5-year median for Current Taxes is $1.0 billion (2024), against an average of $1.2 billion.
• Biggest YoY gain for Current Taxes was 37.88% in 2024; the steepest drop was 57.78% in 2024.
• Year by year, Current Taxes stood at $1.3 billion in 2022, then plunged by 43.07% to $760.7 million in 2023, then surged by 37.88% to $1.0 billion in 2024, then slipped by 8.1% to $963.9 million in 2025, then plunged by 35.25% to $624.1 million in 2026.
• Per Business Quant, the three latest TAK Current Taxes figures stand at $624.1 million (Q1 2026), $963.9 million (Q4 2025), and $834.1 million (Q3 2025).